Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis

Mise à jour : Il y a 4 ans
Référence : NCT00331500

Femme et Homme

Extrait

The purpose of this study is to demonstrate that Olopatadine 0.2% is superior to vehicle in the treatment of the signs and symptoms associated with allergic conjunctivitis or rhinoconjunctivitis.


Critère d'inclusion

  • allergic conjunctivitis

Liens